 |
|
Duration of Anticoagulation Following Venous Thromboembolism
A Meta-analysis
David Ost, MD;
Josh Tepper, MD;
Hanako Mihara, MD, MPH;
Owen Lander, MD;
Raphael Heinzer, MD;
Alan Fein, MD
JAMA. 2005;294:706-715.
Context Patients with venous thromboembolism (VTE) are susceptible to recurrent events, but whether prolonging anticoagulation is warranted in patients with VTE remains controversial.
Objective To review the available evidence and quantify the risks and benefits of extending the duration of anticoagulation in patients with VTE.
Data Sources PubMed, EMBase Pharmacology, the Cochrane database, clinical trial Web sites, and a hand search of reference lists.
Study Selection Included studies were randomized controlled trials with results published from 1969 through 2004 and evaluating the duration of anticoagulation in patients with VTE that measured recurrent VTE. Excluded studies were those enrolling only pure populations of high-risk patients. Two independent reviewers assessed each article for inclusion and exclusion criteria, with adjudication by a third reviewer in cases of disagreement. Fifteen of 67 studies were included in the analysis.
Data Extraction Two independent reviewers performed data extraction using a standardized form, with adjudication by the remainder of the investigators in cases of disagreement. Data regarding recurrent VTE, major bleeding, person-time at risk, and study quality were extracted.
Data Synthesis If patients in the long-term therapy group remained receiving anticoagulation, the risk of recurrent VTE with long- vs short-term therapy was reduced (weighted incidence rate, 0.020 vs 0.126 events/person-year; rate difference, –0.106 [95% confidence interval {CI}, –0.145 to –0.067]; P<.001; pooled incidence rate ratio [IRR], 0.21 [95% CI, 0.14 to 0.31]; P<.001). If anticoagulation in the long-term therapy group was discontinued, the risk reduction was less pronounced (weighted incidence rate, 0.052 vs 0.072 events/person-year; rate difference, –0.020 [95% CI, –0.039 to –0.001]; P = .04; pooled IRR, 0.69 [95% CI, 0.53 to 0.91]; P = .009). The risk of major bleeding with long- vs short-term therapy was similar (weighted incidence rate, 0.011 vs 0.006 events/person-year; rate difference, 0.005 [95% CI, –0.002 to 0.011]; P = .14; pooled IRR, 1.80 [95% CI, 0.72 to 4.51]; P = .21).
Conclusions Patients who receive extended anticoagulation are protected from recurrent VTE while receiving long-term therapy. The clinical benefit is maintained after anticoagulation is discontinued, but the magnitude of the benefit is less pronounced.
Author Affiliations: Center for Pulmonary and Critical Care Medicine, North Shore University Hospital, Manhasset, NY (Dr Ost); Institute for Clinical Evaluative Sciences, Toronto, Ontario (Dr Tepper); Department of Epidemiology, Harvard School of Public Health, Boston, Mass (Dr Mihara); Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Harvard University School of Medicine, Boston (Drs Lander and Heinzer); and New York University School of Medicine, New York, NY (Dr Fein).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Continuing Anticoagulation Following Venous Thromboembolism
Elizabeth Krakow and Thomas L. Ortel
JAMA. 2005;294(24):3088.
EXTRACT
| FULL TEXT
Continuing Anticoagulation Following Venous Thromboembolism—Reply
David Ost
JAMA. 2005;294(24):3088-3089.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Thrombophlebitis
Janet M. Torpy, Alison Burke, and Richard M. Glass
JAMA. 2005;294(6):762.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Avoiding "sticker" shock
Green
Blood 2009;114:930-931.
ABSTRACT
| FULL TEXT
Residual Thrombosis on Ultrasonography to Guide the Duration of Anticoagulation in Patients With Deep Venous Thrombosis: A Randomized Trial
Prandoni et al.
ANN INTERN MED 2009;150:577-585.
ABSTRACT
| FULL TEXT
Preventing recurrent venous thromboembolism
DTB 2009;47:38-40.
ABSTRACT
| FULL TEXT
The potential role of heparin in assisted conception
Nelson and Greer
Hum Reprod Update 2008;14:623-645.
ABSTRACT
| FULL TEXT
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Schulman et al.
Chest 2008;133:257S-298S.
ABSTRACT
| FULL TEXT
Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Kearon et al.
Chest 2008;133:454S-545S.
ABSTRACT
| FULL TEXT
The Risk for Fatal Pulmonary Embolism after Discontinuing Anticoagulant Therapy for Venous Thromboembolism
Douketis et al.
ANN INTERN MED 2007;147:766-774.
ABSTRACT
| FULL TEXT
Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial
Campbell et al.
BMJ 2007;334:674-674.
ABSTRACT
| FULL TEXT
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients
Prandoni et al.
haematol 2007;92:199-205.
ABSTRACT
| FULL TEXT
Diagnosis and treatment of deep-vein thrombosis.
Scarvelis and Wells
CMAJ 2006;175:1087-1092.
ABSTRACT
| FULL TEXT
Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review.
Ho et al.
Arch Intern Med 2006;166:729-736.
ABSTRACT
| FULL TEXT
Review: long term anticoagulation reduces recurrent venous thromboembolism
Witt and Siragusa
Evid. Based Med. 2006;11:45-45.
FULL TEXT
Management of Antiphospholipid Antibody Syndrome: A Systematic Review
Lim et al.
JAMA 2006;295:1050-1057.
ABSTRACT
| FULL TEXT
Venous thromboembolism
Blann and Lip
BMJ 2006;332:215-219.
FULL TEXT
Continuing Anticoagulation Following Venous Thromboembolism
Krakow and Ortel
JAMA 2005;294:3088-3088.
FULL TEXT
Continuing Anticoagulation Following Venous Thromboembolism--Reply
Ost
JAMA 2005;294:3088-3089.
FULL TEXT
What's new in the other general journals
Martyn
BMJ 2005;331:423-424.
FULL TEXT
|
